Vanguard Personalized Indexing Management LLC Acquires 2,346 Shares of GSK plc (NYSE:GSK)

Vanguard Personalized Indexing Management LLC increased its holdings in GSK plc (NYSE:GSK) by 6.3% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 39,439 shares of the pharmaceutical company’s stock after purchasing an additional 2,346 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in GSK were worth $1,462,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of GSK. KCS Wealth Advisory grew its stake in shares of GSK by 1.5% in the third quarter. KCS Wealth Advisory now owns 21,391 shares of the pharmaceutical company’s stock worth $775,000 after acquiring an additional 314 shares during the period. Caprock Group LLC grew its position in GSK by 2.8% in the 4th quarter. Caprock Group LLC now owns 11,513 shares of the pharmaceutical company’s stock worth $430,000 after purchasing an additional 317 shares during the period. Horizon Bancorp Inc. IN raised its stake in GSK by 8.9% during the 4th quarter. Horizon Bancorp Inc. IN now owns 3,961 shares of the pharmaceutical company’s stock valued at $147,000 after buying an additional 323 shares during the last quarter. MONECO Advisors LLC lifted its holdings in shares of GSK by 2.9% during the 4th quarter. MONECO Advisors LLC now owns 12,433 shares of the pharmaceutical company’s stock valued at $461,000 after buying an additional 346 shares during the period. Finally, AdvisorNet Financial Inc boosted its stake in shares of GSK by 1.9% in the 4th quarter. AdvisorNet Financial Inc now owns 20,729 shares of the pharmaceutical company’s stock worth $768,000 after buying an additional 377 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on GSK. Citigroup raised GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th. Morgan Stanley assumed coverage on shares of GSK in a research report on Tuesday, January 23rd. They set an “equal weight” rating for the company. Finally, Guggenheim upgraded shares of GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy”.

GSK Stock Up 0.2 %

GSK stock opened at $44.99 on Friday. The business’s 50-day moving average price is $42.32 and its 200-day moving average price is $39.77. The stock has a market cap of $93.23 billion, a P/E ratio of 16.30, a PEG ratio of 1.93 and a beta of 0.65. GSK plc has a twelve month low of $33.33 and a twelve month high of $45.92. The company has a quick ratio of 0.58, a current ratio of 0.87 and a debt-to-equity ratio of 1.15.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Friday, May 17th will be given a $0.3762 dividend. This is a positive change from GSK’s previous quarterly dividend of $0.36. This represents a $1.50 dividend on an annualized basis and a dividend yield of 3.35%. The ex-dividend date of this dividend is Thursday, May 16th. GSK’s dividend payout ratio is presently 53.26%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.